Analysis of diroximel fumarate data for patients with relapsing forms of multiple sclerosis using related adverse events from the FDA adverse reporting system
Our study identified several potentially important AEs that were not mentioned in the DRF instructions. However, further epidemiologic studies are needed to validate these findings.
Authors
- Jingya Yang (ORCID: https://orcid.org/0000-0002-7419-5133)
- Sun Ying (ORCID: https://orcid.org/0000-0003-4052-2498)
- Lei-Yong Zhao
- Xiaotong Li (ORCID: https://orcid.org/0000-0002-4622-0813)
- Wei Peng (ORCID: https://orcid.org/0000-0001-6823-7942)
- Hong-Yun Wu (ORCID: https://orcid.org/0009-0007-0810-3951)
- Teng Zuo
- Shengzhu Sun
Institutions
- Nanjing University of Chinese Medicine (CN)
- Shandong University of Traditional Chinese Medicine (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1080/14740338.2025.2488318
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47